Healthcare >> CEO Interviews >> August 18, 2022
Bruce Steel, CFA, is a Co-Founder, Director, and Chief Executive Officer of Equillium, Inc. Prior to co-founding Equillium, Mr. Steel was the Founder and Managing Director of BioMed Ventures, the strategic investment arm of BioMed Realty, where he directed investments in over 30 biotechnology companies including Auspex, AnaptysBio, Compass, eFFECTOR, NeoTract and Receptos. Previously, Mr. Steel was co-founder and CEO of Rincon Pharmaceuticals (acquired in 2008), Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. Mr. Steel received his Bachelor of Arts degree from Dartmouth College and Master of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst. Profile
Word count: 1,793
TWST: Can you give us an overview and history of the company?
Mr. Steel: We started Equillium in 2017 to build a company focused on treating
